Berobenatide vs Retatrutide: Pfizer's Trial Data So Far
Berobenatide (PF'3944) is the GLP-1 drug Pfizer gained with Metsera. Its structure, trial data and Phase 3 program, set against retatrutide.
Read article →Every price pulled directly from public vendor catalogs and normalized to $/mg. Catalog snapshot - no rankings, no editor's picks, just the data.
A snapshot of the most-listed peptides.
Public codes at 46 vendors
5% to 50% off with a code. Codes last verified at checkout on November 13, 2026.
23 live at 21 vendors, largest discount first:
Flawless Compounds: 45% off sitewide through Nov 15
Glow Aminos: 45% off sitewide through Nov 15
Nov 13: 15 back in stock · 21 out of stock · 10 price movers · 7 new listings
Price movers, new listings and stock changes across every indexed vendor, recorded every morning. Monthly aggregates are published as open data.
Peptide Deal Finder is a neutral price index for research peptides. We scrape the catalogs of every research peptide vendor we track on a daily basis, normalize prices to USD per milligram so vial sizes are directly comparable across vendors, and present the data without editorial ranking. The site is free to use and requires no signup.
Research peptides are sold by online vendors - also called suppliers or sources - that ship lyophilized vials direct to customers. Peptide Deal Finder tracks vendors with public catalogs and compares their prices per milligram. Browse the vendor index for shipping, payment, and Trustpilot data on the vendors we track, or click any peptide above to see vendor-by-vendor pricing.
Peptide Deal Finder scrapes the public catalog of each indexed vendor daily, extracting product names, vial sizes, prices, and stock availability. We normalize all prices to USD per milligram (or per mL for solvents) so packaging differences across vendors are directly comparable. On each peptide's vendor comparison table, public discount codes are applied to the displayed price next to the code. Index-level $/mg figures use vendors' listed prices. Shipping is not included.
Listing prices and stock availability are refreshed once daily for every indexed vendor's catalog. Pages display "Prices updated X hours ago" timestamps based on the most recent successful scrape per vendor.
Yes. Every listing's price and stock status has been snapshotted daily since April 27, 2026. Each peptide page charts its listings' price history, the price changes page records each day's movers, new listings and stock changes, and monthly aggregates are published as open CSV files with a DOI on the price index data page.
Yes. The sales page lists every vendor sale we have recorded that is running today, with its end date, whether a code is needed, and whether Peptide Deal Finder's own code stacks on top. The coupons page lists each vendor's public code and the date it was last confirmed at checkout. Sale percentages are never applied to displayed prices: a listing shows what the storefront publishes, which already reflects a sale once the vendor posts the sale price. Public codes are applied only on each peptide's vendor comparison table, beside the code.
Peptide Deal Finder participates in vendor affiliate programs where available - when a reader clicks a Buy button, the click is attributed to Peptide Deal Finder and the site earns a small commission if the reader makes a purchase. Affiliate participation does not influence indexing, pricing display, or which vendors appear in search results. Discount codes shown on vendor profiles are public and apply equally regardless of how the reader arrives at the vendor's site. See the disclosure page for full details.
Affiliate commissions on Buy-button clicks are the only monetization. There is no paid placement, no editorial sponsorship, and no signup wall. Vendors cannot pay to be listed, removed, or repositioned in any sort or filter - the index reflects the public peptide-selling research catalogs we can scrape automatically.
Berobenatide (PF'3944) is the GLP-1 drug Pfizer gained with Metsera. Its structure, trial data and Phase 3 program, set against retatrutide.
Read article →FDA will require every approved GLP-1 drug, semaglutide and tirzepatide included, to warn of a potential increased risk of NAION, a rare optic nerve condition.
Read article →Compare mazdutide, retatrutide and survodutide: receptor targets, Phase 3 trial results, approval status in the U.S. and China and price per milligram.
Read article →